http://www.jcps.ac.cn

Journal of Chinese Pharmaceutical Sciences ›› 2018, Vol. 27 ›› Issue (2): 138-140.

• Others • Previous Articles     Next Articles

Information from US FDA——Impact of Severe Weather Conditions on Biological Products & FDA Drug Safety Communication: FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease

www.fda.gov   

  1. http://www.fda.gov
  • Received:2018-02-23 Revised:2018-02-24 Online:2018-03-03 Published:2018-02-25
  • Contact: http://www.fda.gov

Abstract:

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “For patients with stage III lung cancer that cannot be removed surgically, the current approach to prevent progression is chemoradiation. Although a small number of patients may be cured with the chemoradiation, the cancer may eventually progress. Patients now have an approved therapy that has been shown to keep the cancer from progressing for a longer time after chemoradiation.”

Supporting: